High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single-arm clinical study.
facial rejuvenation
helium plasma
helium plasma dermal resurfacing
radiofrequency
rhytid
skin rejuvenation
skin resurfacing
wrinkle
Journal
Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
13
01
2022
received:
06
09
2021
accepted:
30
01
2022
pubmed:
17
2
2022
medline:
14
6
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
A previous multi-center clinical study of low energy (20% power), single-pass helium plasma dermal resurfacing (HPDR) showed positive results but did not fully reveal the true potential of this novel technology. A second multi-center clinical study, reported herein, was therefore undertaken to evaluate efficacy and safety of high energy (40%), double pass HPDR for treatment of facial rhytids (ClinicalTrials.gov Identifier: NCT04185909). Fifty-five eligible subjects seeking improvement in facial rhytids were enrolled for study at one of four investigational sites. All subjects underwent full-face HPDR treatment. The forehead, nose, cheeks, and peri-oral treatment zones were treated at 40% power with two passes whereas the peri-orbital and jawline/mandibular zones were treated at 20% power (up to 40% for jawline/mandibular zone) and one or two passes. Photographic images of the face were captured using the VISIA-CR system. Three-month posttreatment Fitzpatrick Wrinkle and Elastosis Scale (FWS) scores were compared to baseline scores as determined by blinded independent photographic reviewers (IPRs) and study investigators. Blinded IPRs and study investigators observed a ≥1-point FWS improvement in 100% of subjects with mean change in IPR FWS from baseline to the 90-day visit of -3.6 (±1.2). 96.4% of subjects indicated "improvement" in appearance at the 90-day visit utilizing the modified Global Aesthetic Improvement Scale. Evaluation of VISIA-CR data revealed statistically significant improvements in wrinkles, brown spots, and pore counts. Overall, 269 Adverse Events in 55 subjects were reported; most were mild-moderate in severity (99.3%), anticipated (86.2%), and of relatively short duration with most having resolved within 30 days (60.6%) of treatment. Treatment of facial rhytids with high energy, double pass HPDR as detailed herein enables a marked improvement in FWS that parallels or surpasses competing technologies. VISIA-CR analysis demonstrates additional improvements in skin quality with statistically significant quantitative improvements in brown spots and enlarged pores as well as wrinkles. Effective rhytid effacement combines with high subject satisfaction and few unanticipated adverse events for a reasonable benefit-risk ratio.
Sections du résumé
BACKGROUND
A previous multi-center clinical study of low energy (20% power), single-pass helium plasma dermal resurfacing (HPDR) showed positive results but did not fully reveal the true potential of this novel technology. A second multi-center clinical study, reported herein, was therefore undertaken to evaluate efficacy and safety of high energy (40%), double pass HPDR for treatment of facial rhytids (ClinicalTrials.gov Identifier: NCT04185909).
METHODS
Fifty-five eligible subjects seeking improvement in facial rhytids were enrolled for study at one of four investigational sites. All subjects underwent full-face HPDR treatment. The forehead, nose, cheeks, and peri-oral treatment zones were treated at 40% power with two passes whereas the peri-orbital and jawline/mandibular zones were treated at 20% power (up to 40% for jawline/mandibular zone) and one or two passes. Photographic images of the face were captured using the VISIA-CR system. Three-month posttreatment Fitzpatrick Wrinkle and Elastosis Scale (FWS) scores were compared to baseline scores as determined by blinded independent photographic reviewers (IPRs) and study investigators.
RESULTS
Blinded IPRs and study investigators observed a ≥1-point FWS improvement in 100% of subjects with mean change in IPR FWS from baseline to the 90-day visit of -3.6 (±1.2). 96.4% of subjects indicated "improvement" in appearance at the 90-day visit utilizing the modified Global Aesthetic Improvement Scale. Evaluation of VISIA-CR data revealed statistically significant improvements in wrinkles, brown spots, and pore counts. Overall, 269 Adverse Events in 55 subjects were reported; most were mild-moderate in severity (99.3%), anticipated (86.2%), and of relatively short duration with most having resolved within 30 days (60.6%) of treatment.
CONCLUSION
Treatment of facial rhytids with high energy, double pass HPDR as detailed herein enables a marked improvement in FWS that parallels or surpasses competing technologies. VISIA-CR analysis demonstrates additional improvements in skin quality with statistically significant quantitative improvements in brown spots and enlarged pores as well as wrinkles. Effective rhytid effacement combines with high subject satisfaction and few unanticipated adverse events for a reasonable benefit-risk ratio.
Identifiants
pubmed: 35170772
doi: 10.1002/lsm.23524
pmc: PMC9305223
doi:
Substances chimiques
Plasma Gases
0
Helium
206GF3GB41
Banques de données
ClinicalTrials.gov
['NCT04185909']
Types de publication
Case Reports
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
648-662Informations de copyright
© 2022 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
Références
Lasers Surg Med. 2014 Apr;46(4):249-62
pubmed: 24664987
J Cosmet Laser Ther. 2018 Jun;20(3):168-178
pubmed: 29236557
Lasers Med Sci. 2007 Jun;22(2):101-9
pubmed: 17342383
Arch Dermatol. 1996 Apr;132(4):395-402
pubmed: 8629842
Lasers Surg Med. 2022 Jul;54(5):648-662
pubmed: 35170772
Lasers Surg Med. 2009 Mar;41(3):185-8
pubmed: 19291746
Plast Reconstr Surg. 2002 Jan;109(1):308-16; discussion 317-8
pubmed: 11786830
J Clin Aesthet Dermatol. 2018 Dec;11(12):30-39
pubmed: 30666277
J Cosmet Dermatol. 2021 Jun;20(6):1668-1678
pubmed: 33773028
Arch Facial Plast Surg. 2000 Oct-Dec;2(4):279-84
pubmed: 11074725
Lasers Surg Med. 2020 Jan;52(1):23-32
pubmed: 31587330
Arch Dermatol. 2000 Jun;136(6):725-31
pubmed: 10871933
Facial Plast Surg Clin North Am. 2020 Feb;28(1):67-74
pubmed: 31779943
Lasers Surg Med. 2020 Dec;52(10):940-951
pubmed: 32350901
Dermatol Surg. 1998 Mar;24(3):315-20
pubmed: 9537005
Dermatol Surg. 1997 Jul;23(7):519-25
pubmed: 9236869
J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088
pubmed: 30211382